Barclays raised the firm’s price target on Emerson (EMR) to $125 from $118 and keeps an Underweight rating on the shares. The firm sees high investor expectations for the multi-industry sector heading into the Q2 reports. Most companies are positioned to beat estimates and raise guidance despite tepid consumer demand, the analyst tells investors in a research note. However, Barclays sees a neutral risk/reward for stocks in the group despite positive estimate revisions given the recent sector rally.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: